Asian Dividend Stocks To Consider In April 2025

As global markets grapple with economic uncertainty and inflation concerns, Asian indices have shown resilience amidst fluctuating consumer sentiment and trade tensions. In this environment, dividend stocks can offer a measure of stability and income potential for investors seeking to navigate these turbulent times.

Top 10 Dividend Stocks In Asia

Click here to see the full list of 1149 stocks from our Top Asian Dividend Stocks screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Shanghai Zijiang Enterprise Group (SHSE:600210)

Simply Wall St Dividend Rating: ★★★★☆☆

Overview: Shanghai Zijiang Enterprise Group Co., Ltd. operates in the packaging industry and has a market cap of CN¥10.75 billion.

Operations: Shanghai Zijiang Enterprise Group Co., Ltd. generates its revenue from various segments within the packaging industry.

Dividend Yield: 3.5%

Shanghai Zijiang Enterprise Group reported strong earnings growth with net income rising to CNY 808.81 million, but its dividend reliability is questionable due to volatility and lack of free cash flow coverage. Despite a reasonable payout ratio of 59.5% and a competitive dividend yield of 3.53%, the dividends have been unstable over the past decade, experiencing significant drops. The stock's price-to-earnings ratio of 13.3x suggests it is undervalued compared to the broader CN market average.

• Click here and access our complete dividend analysis report to understand the dynamics of Shanghai Zijiang Enterprise Group.
• The analysis detailed in our Shanghai Zijiang Enterprise Group valuation report hints at an inflated share price compared to its estimated value.

Zhejiang Jiuzhou Pharmaceutical (SHSE:603456)

Simply Wall St Dividend Rating: ★★★★☆☆

Overview: Zhejiang Jiuzhou Pharmaceutical Co., Ltd is a contract development and manufacturing organization operating both in China and internationally, with a market cap of CN¥12.98 billion.

Operations: Zhejiang Jiuzhou Pharmaceutical Co., Ltd generates its revenue from its operations as a contract development and manufacturing organization serving both domestic and international markets.

Dividend Yield: 3.4%

Zhejiang Jiuzhou Pharmaceutical's dividend yield of 3.45% ranks in the top 25% of CN market payers but is not well-covered by free cash flows, raising sustainability concerns. Despite a reasonable payout ratio of 64.6%, dividends have been volatile over the past decade, impacting reliability. The stock's price-to-earnings ratio of 18.6x indicates it is undervalued relative to the CN market average. A recent CNY 200 million share buyback plan could enhance shareholder value through an equity incentive strategy.

• Dive into the specifics of Zhejiang Jiuzhou Pharmaceutical here with our thorough dividend report.
• According our valuation report, there's an indication that Zhejiang Jiuzhou Pharmaceutical's share price might be on the expensive side.

Yantai Zhenghai Biotechnology (SZSE:300653)

Simply Wall St Dividend Rating: ★★★★☆☆

Overview: Yantai Zhenghai Biotechnology Co., Ltd. focuses on the research, development, production, and marketing of regenerative medical materials in China with a market cap of CN¥4.15 billion.

Operations: Yantai Zhenghai Biotechnology Co., Ltd. generates its revenue primarily from the research, development, production, and sales of bio-renewable materials, amounting to CN¥383.22 million.

Dividend Yield: 3.4%

Yantai Zhenghai Biotechnology's dividend yield of 3.45% places it among the top 25% in the CN market, supported by earnings and cash flows with payout ratios of 86.3% and 89%, respectively. However, its dividend history is marked by volatility and unreliability over the past seven years, despite recent increases. The stock's price-to-earnings ratio of 24.7x suggests it is undervalued compared to the CN market average, offering potential value for investors seeking growth alongside dividends.

• Take a closer look at Yantai Zhenghai Biotechnology's potential here in our dividend report.
• Our valuation report unveils the possibility Yantai Zhenghai Biotechnology's shares may be trading at a premium.

Taking Advantage

• Explore the 1149 names from our Top Asian Dividend Stocks screener here.
• Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive.
• Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors.

Ready For A Different Approach?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com